Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
Mallinckrodt
AstraZeneca
McKesson

Last Updated: September 26, 2022

Imprimis Pharms Usa Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for IMPRIMIS PHARMS USA, and when can generic versions of IMPRIMIS PHARMS USA drugs launch?

IMPRIMIS PHARMS USA has four approved drugs.

There are two US patents protecting IMPRIMIS PHARMS USA drugs.

There are twenty-three patent family members on IMPRIMIS PHARMS USA drugs in fifteen countries and nine supplementary protection certificates in six countries.

Summary for Imprimis Pharms Usa
International Patents:23
US Patents:2
Tradenames:3
Ingredients:3
NDAs:4

Drugs and US Patents for Imprimis Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Imprimis Pharms Usa MAXITROL dexamethasone; neomycin sulfate; polymyxin b sulfate SUSPENSION/DROPS;OPHTHALMIC 050023-002 Approved Prior to Jan 1, 1982 AT RX Yes Yes See Plans and Pricing See Plans and Pricing
Imprimis Pharms Usa IOPIDINE apraclonidine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020258-001 Jul 30, 1993 AT RX Yes Yes See Plans and Pricing See Plans and Pricing
Imprimis Pharms Usa MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 AT2 RX Yes Yes 8,450,311 See Plans and Pricing Y See Plans and Pricing
Imprimis Pharms Usa IOPIDINE apraclonidine hydrochloride SOLUTION/DROPS;OPHTHALMIC 019779-001 Dec 31, 1987 RX Yes Yes See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Imprimis Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Imprimis Pharms Usa IOPIDINE apraclonidine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020258-001 Jul 30, 1993 4,517,199 See Plans and Pricing
Imprimis Pharms Usa MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 7,671,070*PED See Plans and Pricing
Imprimis Pharms Usa MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 4,990,517*PED See Plans and Pricing
Imprimis Pharms Usa IOPIDINE apraclonidine hydrochloride SOLUTION/DROPS;OPHTHALMIC 019779-001 Dec 31, 1987 5,212,196 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for IMPRIMIS PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 10.5% ➤ Subscribe 2012-02-29

Supplementary Protection Certificates for Imprimis Pharms Usa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0780390 PA2004012 Lithuania See Plans and Pricing PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0780390 PA2004012,C0780390 Lithuania See Plans and Pricing PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0350733 SPC/GB03/034 United Kingdom See Plans and Pricing PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
1581193 SPC/GB12/047 United Kingdom See Plans and Pricing PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.